TABLE 199: DISCONTINUATION — ALL-CAUSE(S)

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1	(6) SOF12 + LDV12	0	109	0%
		(7) SOF24 + LDV24	2	109	2%
		(10) SOF12 + LDV12 + RBV12	0	111	0%
		(11) SOF24 + LDV24 + RBV24	1	111	1%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	95	0%
Bacon et al., 2011 RESPOND2	1	(1) PR48	57	80	71%
		(74) B32 PR36-48 RGT	58	162	36%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	0	77	0%
		(10) SOF12 + LDV12 + RBV12	1	78	1%
Dieterich et al., 2014-2+3+4	1	(69) SIM12 PR24-48 RGT or SIM12 PR48	15	53	28%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	1	79	1%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	0	10	0%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	1	103	1%
Jensen et al., 2015-1 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	19	354	5%
Jensen et al., 2015-2 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	0	44	0%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	14	87	16%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	3	47	6%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
		(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2014 COSMOS	1	(72) SOF12 + SIM12 + RBV12	0	27	0%
		(5) SIM12 + SOF12	0	14	0%
Lok et al., 2014 DUAL A2	1b	(17) DCV24 + ASU24	6	20	30%
Lok et al., 2014 QUAD B2	1	(18) DCV24 + ASU24 + PR24	0	21	0%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	28	205	14%
Mizokami et al., 2015	1	(6) SOF12 + LDV12	0	88	0%
		(10) SOF12 + LDV12 + RBV12	0	87	0%
Molina et al., 2015 PHOTON-2	3	(4) SOF24 + RBV24	2	49	4%
Muir et al., 2015 UNITY-2	1+6	(25) DCV12 + ASU12 + BEC12 + RBV12	2	45	4%
		(26) DCV12 + ASU12 + BEC12	1	45	2%
Nelson D. et al., 2015 ALLY-3	3	(19) DCV12 + SOF12	0	51	0%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Omata et al., 2014	2	(3) SOF12 + RBV12	0	63	0%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pol et al., 2015	1	(40) SOF12 + PR12	0	80	0%
Poordad et al., 2015 UNITY-1	1	(26) DCV12 + ASU12 + BEC12	4	103	4%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	76	384	20%
Reddy et al., 2015 ATTAIN		(68) SIM12 PR48	51	379	13%
Sulkowski et al., 2014-3	3	(4) SOF24 + RBV24	0	17	0%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	1	51	2%
Zeuzem et al., 2014 SAPPHIRE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	5	297	2%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	44	132	33%
Zeuzem et al., 2011 REALIZE		(39) T12 PR48 q8	51	266	19%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	40	66	61%
Zeuzem et al., 2014 ASPIRE		(68) SIM12 PR48	16	66	24%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.